featured-image

skynesher/E+ via Getty Images Ipsen ( OTCPK:IPSEY ) and Foreseen Biotechnology on Thursday announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate, which targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation. Preclinical efficacy of FS001 was demonstrated in multi-drug resistant cancer models. The agreement gives Ipsen ( OTCPK:IPSEY ) exclusive worldwide rights to develop, manufacture and commercialize FS001, the companies said.

“We are excited to add FS001, the second ADC Ipsen has in-licensed this year, to our growing pipeline,” said Mary Jane Hinrichs, SVP and Head of Early Development at Ipsen ( OTCPK:IPSEY ). “As we prepare for the initiation of a Phase I clinical trial, we will evaluate FS001 in selected solid tumor types, which we hope will deliver critical new treatments for people living with cancer around the world.” Source: Press Release More on Ipsen S.



A. Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China Ipsen expands collaboration agreement with Exelixis Historical earnings data for Ipsen S.A.

Dividend scorecard for Ipsen S.A. Financial information for Ipsen S.

A..

Back to Health Page